Investigators Hope Glioma Trial of Eflornithine Will Clinch Approval
Eflornithine (α-Difluoromethylornithine) has been investigated for over 30 years as a potential neuro-oncology agent and shown activity against recurrent gliomas, but it has not gained approval as a therapy option for patients with cancer. Investigators are looking to change that with the phase III STELLAR trial (NCT02796261).
Source: OncLive